Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Int J Hyg Environ Health. 2020 Apr 8;227:113522. doi: 10.1016/j.ijheh.2020.113522

Table 4.

Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between lipid-adjusted plasma levels of polychlorinated biphenyls and 20-year conditional mortality in the CBCSI women diagnosed with invasive breast cancer in 1993–1996 (n = 748).

20-year Conditional All-Cause Mortality 20-year Conditional Breast Cancer-Specific Mortality
PCBs (μ/g lipid) Deaths (n = 259) Censored (n = 356) Model 1a Model 2b Deaths (n = 97) Censored (n = 518) Model 1a Model 2b
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
PCB74
 Tertile 1 60 146 1.00 (Reference) 1.00 (Reference) 36 170 1.00 (Reference) 1.00 (Reference)
 Tertile 2 80 133 1.12 (0.79–1.57) 0.91 (0.63–1.33) 34 179 1.02 (0.63–1.64) 0.84 (0.50–1.42)
 Tertile 3 119 77 1.61 (1.14–2.28) 1.54 (1.06–2.24) 27 169 1.14 (0.66–1.96) 1.23 (0.70–2.18)
  Ln(PCB74) 1.19 (1.00–1.40) 1.17 (0.98–1.41) 1.04 (0.81–1.34) 1.11 (0.85–1.46)
PCB99
 Tertile 1 65 146 1.00 (Reference) 1.00 (Reference) 36 175 1.00 (Reference) 1.00 (Reference)
 Tertile 2 80 124 1.15 (0.82–1.60) 1.33 (0.92–1.92) 34 170 0.99 (0.61–1.58) 1.15 (0.68–1.92)
 Tertile 3 112 82 1.49 (1.07–2.08) 1.57 (1.08–2.29) 27 167 0.97 (0.57–1.65) 1.11 (0.63–1.96)
  Ln(PCB99) 1.16 (0.99–1.36) 1.19 (0.99–1.43) 0.99 (0.77–1.28) 1.10 (0.83–1.45)
PCB118
 Tertile 1 63 144 1.00 (Reference) 1.00 (Reference) 32 175 1.00 (Reference) 1.00 (Reference)
 Tertile 2 81 128 1.23 (0.88–1.71) 1.46 (1.01–2.10) 39 170 1.38 (0.86–2.21) 1.79 (1.07–2.98)
 Tertile 3 113 80 1.52 (1.08–2.13) 1.74 (1.19–2.56) 26 167 1.15 (0.66–2.00) 1.57 (0.86–2.86)
  Ln(PCB118) 1.24 (1.05–1.47) 1.37 (1.12–1.68) 1.06 (0.81–1.39) 1.23 (0.90–1.69)
PCB138
 Tertile 1 59 145 1.00 (Reference) 1.00 (Reference) 34 170 1.00 (Reference) 1.00 (Reference)
 Tertile 2 81 127 1.23 (0.88–1.73) 1.24 (0.85–1.80) 33 175 1.12 (0.69–1.82) 1.24 (0.73–2.10)
 Tertile 3 117 80 1.64 (1.16–2.31) 1.72 (1.18–2.50) 30 167 1.19 (0.71–2.01) 1.40 (0.80–2.46)
  Ln(PCB138) 1.21 (0.99–1.48) 1.20 (0.97–1.50) 1.01 (0.75–1.37) 1.08 (0.78–1.50)
PCB146
 Tertile 1 53 151 1.00 (Reference) 1.00 (Reference) 35 169 1.00 (Reference) 1.00 (Reference)
 Tertile 2 76 131 1.24 (0.87–1.77) 1.11 (0.75–1.63) 27 180 0.84 (0.51–1.40) 0.78 (0.45–1.36)
 Tertile 3 126 71 2.05 (1.42–2.95) 1.88 (1.26–2.80) 34 163 1.38 (0.82–2.33) 1.35 (0.77–2.36)
  Ln(PCB146) 1.35 (1.15–1.59) 1.30 (1.09–1.55) 1.19 (0.93–1.53) 1.19 (0.91–1.55)
PCB153
 Tertile 1 56 148 1.00 (Reference) 1.00 (Reference) 32 172 1.00 (Reference) 1.00 (Reference)
 Tertile 2 81 126 1.30 (0.92–1.84) 1.39 (0.95–2.02) 33 174 1.17 (0.72–1.91) 1.33 (0.78–2.25)
 Tertile 3 120 78 1.80 (1.27–2.56) 1.96 (1.33–2.89) 32 166 1.42 (0.84–2.40) 1.60 (0.90–2.86)
  Ln(PCB153) 1.27 (1.03–1.58) 1.34 (1.05–1.70) 1.07 (0.77–1.47) 1.27 (0.89–1.82)
PCB156 + PCB171c
 Tertile 1 64 135 1.00 (Reference) 1.00 (Reference) 41 158 1.00 (Reference) 1.00 (Reference)
 Tertile 2 81 128 1.12 (0.81–1.56) 1.15 (0.80–1.65) 30 179 0.79 (0.49–1.27) 0.91 (0.55–1.52)
 Tertile 3 114 93 1.27 (0.91–1.77) 1.33 (0.92–1.93) 26 181 0.77 (0.46–1.31) 0.97 (0.55–1.70)
 Ln(PCB156 + PCB171) 1.11 (0.97–1.27) 1.12 (0.96–1.30) 0.90 (0.73–1.11) 0.96 (0.76–1.20)
PCB170 + PCB190c
 Tertile 1 58 139 1.00 (Reference) 1.00 (Reference) 32 165 1.00 (Reference) 1.00 (Reference)
 Tertile 2 86 117 1.30 (0.93–1.82) 1.16 (0.81–1.68) 32 171 1.18 (0.72–1.95) 1.07 (0.63–1.82)
 Tertile 3 109 84 1.56 (1.11–2.19) 1.44 (0.99–2.11) 30 163 1.30 (0.77–2.19) 1.16 (0.66–2.06)
  Ln(PCB170 + PCB190) 1.21 (1.04–1.41) 1.18 (1.00–1.39) 1.14 (0.91–1.44) 1.14 (0.89–1.46)
PCB180
 Tertile 1 64 137 1.00 (Reference) 1.00 (Reference) 33 168 1.00 (Reference) 1.00 (Reference)
 Tertile 2 95 118 1.21 (0.87–1.67) 1.15 (0.81–1.64) 38 175 1.30 (0.81–2.09) 1.20 (0.72–2.00)
 Tertile 3 98 97 1.20 (0.85–1.67) 1.23 (0.85–1.78) 25 170 0.94 (0.55–1.62) 1.00 (0.57–1.78)
  Ln(PCB180) 1.07 (0.88–1.30) 1.12 (0.88–1.41) 1.05 (0.78–1.41) 1.09 (0.79–1.52)
PCB182 + PCB187c
 Tertile 1 54 154 1.00 (Reference) 1.00 (Reference) 36 172 1.00 (Reference) 1.00 (Reference)
 Tertile 2 84 122 1.39 (0.98–1.98) 1.39 (0.95–2.04) 35 171 1.15 (0.58–1.68) 1.18 (0.70–1.98)
 Tertile 3 121 80 1.70 (1.17–2.47) 1.82 (1.21–2.74) 26 175 0.91 (0.52–1.61) 0.95 (0.52–1.74)
  Ln(PCB182 + PCB187) 1.23 (1.06–1.42) 1.20 (1.03–1.41) 1.00 (0.81–1.24) 0.99 (0.79–1.24)
PCB194
 Tertile 1 60 142 1.00 (Reference) 1.00 (Reference) 40 162 1.00 (Reference) 1.00 (Reference)
 Tertile 2 84 125 1.12 (0.80–1.57) 1.00 (0.69–1.45) 31 178 0.86 (0.53–1.38) 0.74 (0.44–1.24)
 Tertile 3 115 89 1.31 (0.92–1.85) 1.34 (0.91–1.98) 26 178 0.83 (0.49–1.43) 0.84 (0.47–1.51)
  Ln(PCB194) 1.09 (0.92–1.29) 1.07 (0.88–1.29) 0.88 (0.68–1.13) 0.87 (0.66–1.14)
PCB196 + PCB203c
 Tertile 1 53 152 1.00 (Reference) 1.00 (Reference) 39 166 1.00 (Reference) 1.00 (Reference)
 Tertile 2 89 122 1.39 (0.98–1.98) 1.28 (0.87–1.89) 32 179 0.95 (0.58–1.53) 0.81 (0.48–1.38)
 Tertile 3 117 82 1.64 (1.12–2.39) 1.45 (0.95–2.20) 26 173 1.00 (0.57–1.74) 0.80 (0.44–1.45)
  Ln(PCB196 + PCB203) 1.23 (1.01–1.48) 1.13 (0.92–1.39) 26 173 0.97 (0.74–1.28) 0.87 (0.65–1.17)
PCB201
 Tertile 1 60 150 1.00 (Reference) 1.00 (Reference) 38 172 1.00 (Reference) 1.00 (Reference)
 Tertile 2 85 124 1.30 (0.93–1.82) 1.18 (0.82–1.71) 34 175 1.08 (0.67–1.73) 0.97 (0.59–1.61)
 Tertile 3 114 82 1.68 (1.18–2.40) 1.38 (0.94–2.04) 25 171 1.15 (0.66–2.00) 0.85 (0.47–1.53)
  Ln(PCB201) 1.21 (1.04–1.41) 1.11 (0.94–1.32) 1.01 (0.81–1.26) 0.89 (0.70–1.13)
Total PCBs
 Tertile 1 56 148 1.00 (Reference) 1.00 (Reference) 35 169 1.00 (Reference) 1.00 (Reference)
 Tertile 2 85 128 1.42 (1.01–1.99) 1.49 (1.03–2.16) 33 180 1.08 (0.67–1.75) 1.19 (0.71–1.98)
 Tertile 3 118 80 1.71 (1.21–2.43) 1.73 (1.17–2.56) 29 169 1.17 (0.69–1.99) 1.26 (0.70–2.27)
  Ln(Total PCBs) 1.35 (1.07–1.70) 1.36 (1.04–1.77) 1.13 (0.78–1.64) 1.20 (0.80–1.81)

Carolina Breast Cancer Study (CBCS) participants were diagnosed with invasive breast cancer from 1993 to 1996 (Phase I) and followed-up for vital status through December 31, 2016. Conditional analyses are among women who survived > 5 years.

a

Adjusted for age at diagnosis (continuous in years) and race (black vs. white).

b

Adjusted for age at diagnosis (continuous in years), race (black vs. white), smoking status (never, former, and current smoker), education (less than high school, high school, and college or greater), BMI (< 25.0, 25.0–29.9, ≥30.0 kg/m2), parity/lactation history (nulliparous, parous/never lactated, parous/ever lactated), stage (III/IV vs. I/II), and ER status (ER+ vs. ER−).

c

These analytes are quantitated and reported as the sum of their concentrations because they co-elute during GC analysis.